QuorumCivic. Hidden in plain sight Get the app
Bill intelligence
Full Simple

NIH to map young adult cancer crisis, coordinate federal research push

H.R. 11011 — Asal Sayas National Strategy on Young Adult Cancers Act · Filed by André Carson (D-IN) · 1 cosponsor · Introduced Nov 12, 2026 · Referred to committee

92%
Transparency
Typical bill: 85%
8/100
Hidden-provision risk
Typical bill: 15/100
Public Health Strategy Directive

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This bill requires the National Institutes of Health to develop a comprehensive national strategy to address rising cancer rates in young adults (ages 18–49) within 18 months. The strategy must inventory current research, launch public and healthcare-provider education campaigns, identify research priorities, establish a federal coordinating committee, and create an online clearinghouse with cancer information and clinical trial data. No new funding is authorized; the bill directs existing NIH resources to focus on young adult cancers, which have risen 79% globally since 1990 and now cost the U.S. $50–80 billion annually.

Why we flagged it

The bill's operative mechanism is a mandate to NIH to develop and coordinate a multi-agency strategy addressing a documented public health crisis (rising young adult cancer rates). It is not a funding bill, a regulatory change, or a private carve-out—it is a directive to federal agencies to assess, plan, and communicate about an underaddressed disease burden.

What the text implies

  • The bill does not authorize new appropriations, so implementation depends on NIH reprioritizing existing budgets—actual resource allocation to young adult cancer research remains uncertain and subject to future appropriations decisions.
  • The Federal Coordinating Committee includes 'representatives of the biomedical industry,' creating a formal advisory role for private pharmaceutical and device manufacturers in shaping national cancer research priorities—potential for industry influence on research agenda.
  • The online clearinghouse will aggregate clinical trial information and research funding opportunities, potentially directing patient enrollment and research dollars toward trials and institutions represented on the coordinating committee.
  • The bill mandates education campaigns targeting healthcare providers (primary care, OB/GYN, pulmonary, GI specialists) but does not establish enforcement mechanisms or accountability for adoption of new screening/diagnostic practices.
  • Naming the strategy after 'Asal Sayas' (a person not identified in the bill text) without explanation or context may reflect a commemorative intent not apparent from the legislative language alone.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Young adults with cancer face a 7-month diagnostic delay versus 1 month for older patients, and current screening criteria exclude many at-risk young people. This bill directs federal resources to close research gaps, improve provider education, and establish a public clearinghouse—directly addressing barriers to early detection and treatment. The strategy costs no new appropriations (it redirects existing NIH capacity) and benefits a vulnerable population facing rising cancer incidence and wors

Who stands to gain

  • biomedical research institutions (NIH-funded universities and research centers)
  • pharmaceutical and biotechnology companies (through research funding and clinical trial participatio
  • healthcare providers and health systems (through education and clinical practice guidance)
  • patient advocacy organizations (represented on coordinating committee)

Named in the bill

National Institutes of Health (NIH), National Cancer Institute (NCI), Centers for Disease Control and Prevention (CDC), Centers for Medicare & Medicaid Services (CMS), Food and Drug Administration (FDA), Department of Veterans Affairs, Department of Defense, Environmental Protection Agency (EPA), National Science Foundation (NSF), Advanced Research Projects Agency–Health (ARPA-H), Indian Health Service, United States Preventive Services Task Force

Where it stands

1 cosponsor: 1 Republicans.

  • Nov 12, 2026 — Introduced · Congress.gov: “Introduced in House”
  • Nov 12, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

How this was measured

Analysis — Quorum's AI read the bill text published by Congress.gov (13,469 characters) on Nov 14, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.

Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.

As of — page rendered 2026-11-22.

“NIH to map young adult cancer crisis, coordinate federal research push” QuorumCivic. https://share.quorumcivic.app/bill/119/hr11011 Report an error

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record

The week in bills

One email, Sunday: what Congress passed, what it changed, and who paid.

One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.